Compare LCNB & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | CRDL |
|---|---|---|
| Founded | 1877 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 226.6M |
| IPO Year | 1999 | 2017 |
| Metric | LCNB | CRDL |
|---|---|---|
| Price | $19.47 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 23.0K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $6,445,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $22.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.31 | $0.88 |
| 52 Week High | $21.32 | $2.34 |
| Indicator | LCNB | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 55.06 |
| Support Level | $19.01 | $0.97 |
| Resistance Level | $20.48 | $2.28 |
| Average True Range (ATR) | 0.47 | 0.16 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 51.62 | 27.08 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.